Market Trends of Global Autologous Cell Therapy Industry
This section covers the major market trends shaping the Autologous Cell Therapy Market according to our research experts:
Musculoskeletal Disorder Segment is Expected to Hold the Largest Market Share in the Autologous Cell Therapy Market
The musculoskeletal disorders segment is expected to drive the demand for autologous cell therapy for effective treatment. The rise in musculoskeletal disorders among the global population is expected to contribute to the growth of the studied segment along with the launch of innovative autologous cell therapies.
The Key facts published by World Heart Organization (WHO) in February 2021 reported that about 1.71 billion people have musculoskeletal conditions worldwide. Musculoskeletal conditions are the leading contributor to disability worldwide, with low back pain being the single leading cause of disability in 160 countries. Among musculoskeletal disorders, low back pain causes the highest burden with a prevalence of 568 million people. According to the same source, the aging population in the world is increasing, and the number of people with musculoskeletal conditions is rapidly increasing. Musculoskeletal conditions are also the biggest contributor to years lived with disability (YLDs) worldwide with approximately 149 million YLDS, accounting for 17% of all YLDs worldwide. Thus, the increasing number of musculoskeletal disorders is expected to increase the need for effective therapies such as autologous therapies, thereby contributing to the growth of the market.
Also, according to Work-Related Musculoskeletal Disorders statistics in Great Britain, in 2021, 470,000 people suffer from work-related musculoskeletal disorders which are new or long-standing in the year 2020-2021. In the future, such incidence of musculoskeletal disrders conditions are expected to drive the demand for effective therapies which will accelerate the segment growth in the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall autologous cell therapy market, throughout the forecast period. This is owing to factors such as the rising incidence of chronic diseases such as cancer, a blood disorder, autoimmune diseases, and other diseases, and the availability of advanced healthcare infrastructure among the major factors.
For instance, according to the American Cancer Society's report 2022 over 1.9 million new cancer cases are expected to be diagnosed in the United States in 2022. Additionally, 80% of the people diagnosed with cancer in the United States are 55 years of age or older and 57% are 65 or older Thus, due to the high prevalence of cancer, and the rising affected geriatric population, the demand for diagnostics and treatment is also high in the country which is expected to drive the growth in the studied market in the United States.
As per an October 2021 update by the National Cancer Institute, acute myeloid leukemia is the most common type of acute leukemia in adults. In addition, as per the 2021 statistics by the Leukemia & Lymphoma Society, an estimated 397,501 people are living with or in remission from leukemia in the United States. The growing burden of blood disorders such as leukemia is expected to surge the demand for autologous cell therapy, thereby contributing to the growth of the market in this region
